NCT02269163 - Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 26, 2016

Primary Completion Date

January 11, 2019

Study Completion Date

January 11, 2019

Conditions

Primary Immunodeficiency

Interventions

BIOLOGICAL

Immune Globulin Intravenous

Gammargard, Gammaplex,Gamunex, or Octogam IGIV Product

BIOLOGICAL

Prometic's Immune Globulin Intravenous 10%

Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)

Trial Locations (13)

Duke University Medical Center, Durham

Allergy Associates of the Palm Beaches, North Palm Beach

Johns Hopkins All Children's Hospital, St. Petersburg

Optimed Research, Columbus

Fort Wayne Medical Institute, Fort Wayne

Rush University Medical Center, Chicago

St. Louis University, St Louis

Dallas Allergy Immunology, Dallas

Immunoe International Research, Centennial

National Jewish Hospital, Denver

Children's Hospital Los Angeles, Los Angeles

University of California, Irvine, Irvine

Bellingham Asthma, Allergy and Immunology Clinic, Bellingham